<?xml version="1.0" ?> <!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd"> <PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33622238</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1880-6562</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>The journal of physiological sciences : JPS</Title><ISOAbbreviation>J Physiol Sci</ISOAbbreviation></Journal><ArticleTitle>Role of PGE<sub>2</sub> in colonic motility: PGE<sub>2</sub> attenuates spontaneous contractions of circular smooth muscle via EP<sub>4</sub> receptors in the rat colon.</ArticleTitle><Pagination><MedlinePgn>8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12576-021-00791-4</ELocationID><Abstract><AbstractText>Colonic motor activity is important for the formation and propulsion of feces. The production of prostaglandins (PGs) in colonic tissue is considered to play a critical role in the generation and regulation of colonic motility. In this study, we investigated the inhibitory effects of PGE<sub>2</sub> and selective agonists of four EP receptors on the spontaneous phasic contractions, called 'giant contractions' (GCs), of mucosa-free circular smooth muscle strips from the rat middle colon. Neural blockade with tetrodotoxin (TTX) increased the frequency and amplitude of the GCs by about twofold. However, inhibiting PG production with piroxicam reduced the GC frequency in the presence of TTX, but did not affect the GC amplitude. In the presence of both TTX and piroxicam, exogenous PGE<sub>2</sub> and each EP receptor agonist were cumulatively added to the tissue bath. In this setting, PGE<sub>2</sub>, the EP<sub>2</sub> agonist ONO-AE1-259, and the EP<sub>4</sub> agonist ONO-AE1-329, but not the EP<sub>1</sub> agonist ONO-AE-DI-004 or the EP<sub>3</sub> agonist ONO-AE-248, concentration-dependently reduced the GC frequency and amplitude. The PGE<sub>2</sub>-induced inhibition of GC frequency and amplitude was inhibited by the EP<sub>4</sub> antagonist ONO-AE3-208, but not by the EP<sub>1/2</sub> antagonist AH6809. Immunohistochemistry revealed the EP<sub>2</sub> and EP<sub>4</sub> receptors were localized in perinuclear sites in circular smooth muscle cells. EP<sub>2</sub> immunoreactivity was also located in GFAP-immunoreactive enteroglia, whereas EP<sub>4</sub> immunoreactivity was also located in HU (embryonic lethal, abnormal vision [ELAV] protein; a marker of all myenteric neurons)-immunoreactive myenteric nerve cell bodies. These results suggest that the PGs produced in the colonic tissue inhibit the GC frequency and amplitude of circular muscle in the rat middle colon, and is mediated by EP<sub>4</sub> receptors expressed in the smooth muscle cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karaki</LastName><ForeName>Shin-Ichiro</ForeName><Initials>SI</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8525-2965</Identifier><AffiliationInfo><Affiliation>Laboratory of Physiology, Department of Environmental Life Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan. karaki@u-shizuoka-ken.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Physiology, Department of Environmental Life Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Testing and Research Laboratories, HAMRI Co., Ltd., 2654-3 Osaki, Koga, Ibaraki, 306-0101, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Physiol Sci</MedlineTA><NlmUniqueID>101262417</NlmUniqueID><ISSNLinking>1880-6546</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018679">Cholinergic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000620723">E-prostanoid 3 receptor, zebrafish</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058306">Receptors, Prostaglandin E, EP1 Subtype</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058307">Receptors, Prostaglandin E, EP2 Subtype</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058308">Receptors, Prostaglandin E, EP3 Subtype</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058309">Receptors, Prostaglandin E, EP4 Subtype</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026941">Sodium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>13T4O6VMAM</RegistryNumber><NameOfSubstance UI="D010894">Piroxicam</NameOfSubstance></Chemical><Chemical><RegistryNumber>4368-28-9</RegistryNumber><NameOfSubstance UI="D013779">Tetrodotoxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8Y164V895Y</RegistryNumber><NameOfSubstance UI="D002217">Carbachol</NameOfSubstance></Chemical><Chemical><RegistryNumber>K7Q1JQR04M</RegistryNumber><NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002217" MajorTopicYN="N">Carbachol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018679" MajorTopicYN="N">Cholinergic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005769" MajorTopicYN="N">Gastrointestinal Motility</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010894" MajorTopicYN="N">Piroxicam</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058306" MajorTopicYN="N">Receptors, Prostaglandin E, EP1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058307" MajorTopicYN="N">Receptors, Prostaglandin E, EP2 Subtype</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058308" MajorTopicYN="N">Receptors, Prostaglandin E, EP3 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058309" MajorTopicYN="N">Receptors, Prostaglandin E, EP4 Subtype</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026941" MajorTopicYN="N">Sodium Channel Blockers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013779" MajorTopicYN="N">Tetrodotoxin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029961" MajorTopicYN="N">Zebrafish Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colonic motility</Keyword><Keyword MajorTopicYN="N">EP receptor</Keyword><Keyword MajorTopicYN="N">Giant contraction</Keyword><Keyword MajorTopicYN="N">Giant migrating contraction</Keyword><Keyword MajorTopicYN="N">Prostaglandin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>02</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33622238</ArticleId><ArticleId IdType="doi">10.1186/s12576-021-00791-4</ArticleId><ArticleId IdType="pii">10.1186/s12576-021-00791-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sarna SK (2006) Molecular, functional, and pharmacological targets for the development of gut promotility drugs. Am J Physiol Gastrointest Liver Physiol 291:G545–G555</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00122.2006</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Johnson CP, Adams MB, Sarna SK (2002) Cholinergic and nitrergic regulation of in vivo giant migrating contractions in rat colon. Am J Physiol Gastrointest Liver Physiol 283:G544–G552</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00114.2001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez A, Sarna SK (2001) Different types of contractions in rat colon and their modulation by oxidative stress. Am J Physiol Gastrointest Liver Physiol 280:G546–G554</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.2001.280.4.G546</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarna SK (1991) Physiology and pathophysiology of colonic motor activity (1). Dig Dis Sci 36:827–862</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01311244</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders KM (1996) A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology 111:492–515</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.1996.v111.pm8690216</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton EW, Main IH (1963) A Comparison of the biological activities of four prostaglandins. Br J Pharmacol Chemother 21:182–189</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.1963.tb01514.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett A, Eley KG, Scholes GB (1968) Effect of prostaglandins E1 and E2 on intestinal motility in the guinea-pig and rat. Br J Pharmacol 34:639–647</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.1968.tb08493.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Burakoff R, Percy WH (1992) Studies in vivo and in vitro on effects of PGE2 on colonic motility in rabbits. Am J Physiol 262:G23–G29</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.1992.262.1.C23</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk CD, Furci L, FitzGerald GA, Grygorczyk R, Rochette C, Bayne MA, Abramovitz M, Adam M, Metters KM (1993) Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem 268:26767–26772</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)74379-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam M, Boie Y, Rushmore TH, Muller G, Bastien L, McKee KT, Metters KM, Abramovitz M (1994) Cloning and expression of three isoforms of the human EP3 prostanoid receptor. FEBS Lett 338:170–174</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(94)80358-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan JW, Bailey TJ, Pepperl DJ, Pierce KL, Bogardus AM, Donello JE, Fairbairn CE, Kedzie KM, Woodward DF, Gil DW (1994) Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 46:213–220</Citation><ArticleIdList><ArticleId IdType="pubmed">8078484</ArticleId></ArticleIdList></Reference><Reference><Citation>Watabe A, Sugimoto Y, Honda A, Irie A, Namba T, Negishi M, Ito S, Narumiya S, Ichikawa A (1993) Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J Biol Chem 268:20175–20178</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(20)80710-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda A, Sugimoto Y, Namba T, Watabe A, Irie A, Negishi M, Narumiya S, Ichikawa A (1993) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J Biol Chem 268:7759–7762</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)53022-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuyama M, Nishigaki N, Sugimoto Y, Morimoto K, Negishi M, Narumiya S, Ichikawa A (1995) The mouse prostaglandin E receptor EP2 subtype: cloning, expression, and northern blot analysis. FEBS Lett 372:151–156</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(95)00966-D</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishigaki N, Negishi M, Honda A, Sugimoto Y, Namba T, Narumiya S, Ichikawa A (1995) Identification of prostaglandin E receptor “EP2” cloned from mastocytoma cells EP4 subtype. FEBS Lett 364:339–341</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(95)00421-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Boie Y, Stocco R, Sawyer N, Slipetz DM, Ungrin MD, Neuschafer Rube F, Puschel GP, Metters KM, Abramovitz M (1997) Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol 340:227–241</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(97)01383-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey I, Lejeune M, Chadee K (2006) Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol 149:611–623</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0706923</ArticleId></ArticleIdList></Reference><Reference><Citation>Iizuka Y, Kuwahara A, Karaki S (2014) Role of PGE2 in the colonic motility: PGE<sub>2</sub> generates and enhances spontaneous contractions of longitudinal smooth muscle in the rat colon. J Physiol Sci 64:85–96</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12576-013-0295-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Cutillas M, Mane N, Gallego D, Jimenez M, Martin MT (2014) EP2 and EP4 receptors mediate PGE<sub>2</sub> induced relaxation in murine colonic circular muscle: pharmacological characterization. Pharmacol Res 90:76–86</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2014.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6:65–70</Citation></Reference><Reference><Citation>Fairman CL, Clagett-Dame M, Lennon VA, Epstein ML (1995) Appearance of neurons in the developing chick gut. Dev Dyn 204:192–201</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aja.1002040210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji I, Karaki S, Fukami Y, Terasaki M, Kuwahara A (2009) Secretory effects of a luminal bitter tastant and expressions of bitter taste receptors, T2Rs, in the human and rat large intestine. Am J Physiol Gastrointest Liver Physiol 296:G971-981</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.90514.2008</ArticleId></ArticleIdList></Reference><Reference><Citation>Beubler E, Juan H (1978) PGE-release, blood flow and transmucosal water movement after mechanical stimulation of the rat jejunal mucosa. Naunyn Schmiedebergs Arch Pharmacol 305:91–95</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00497010</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi XZ, Lin YM, Powell DW, Sarna SK (2011) Pathophysiology of motility dysfunction in bowel obstruction: role of stretch-induced COX-2. Am J Physiol Gastrointest Liver Physiol 300:G99–G108</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00379.2010</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsui R, Ono S, Karaki S, Kuwahara A (2005) Propionate modulates spontaneous contractions via enteric nerves and prostaglandin release in the rat distal colon. Jpn J Physiol 55:331–338</Citation><ArticleIdList><ArticleId IdType="doi">10.2170/jjphysiol.RP000205</ArticleId></ArticleIdList></Reference><Reference><Citation>Asfaha S, MacNaughton WK, Appleyard CB, Chadee K, Wallace JL (2001) Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 281:G635–G644</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.2001.281.3.G635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao HW, Hyman PE, Finn SE, Snape WJ Jr (1988) Effect of prostaglandin E<sub>2</sub> on rabbit colonic smooth muscle cell contraction. Am J Physiol Gastrointest Liver Physiol 255:G807-812</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.1988.255.6.G807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoda Y, Karaki S, Shimoda Y, Kuwahara A (2002) Substance P-evoked Cl<sup>-</sup> secretion in guinea pig distal colonic epithelia: interaction with PGE<sub>2</sub>. Am J Physiol Gastrointest Liver Physiol 283:G347-356</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00504.2001</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins D, Hogan AM, Skelly MM, Baird AW, Winter DC (2009) Cyclic AMP-mediated chloride secretion is induced by prostaglandin F2alpha in human isolated colon. Br J Pharmacol 158:1771–1776</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2009.00464.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosa AS, Hansen MB, Tilotta CM, Bindslev N (2008) EP4 and EP2 receptor subtypes involved in colonic secretion in rat. Basic Clin Pharmacol Toxicol 103:214–221</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-7843.2008.00257.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T (2000) The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141:1554–1559</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endo.141.4.7405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Tsuboi K, Sugimoto Y, Kobayashi T, Miyachi Y, Ichikawa A, Narumiya S (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109:883–893</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI0214459</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>